Latest news on J&J’s NSCLC approval, Bristol Myers Squibb’s big TIGIT bet, #ASCO21 and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Be sure to check out our 60 over 60 special — our way of honoring those who have left lasting legacies in biopharma. We have already received some thoughtful feedback from readers, which we always appreciate. Aside from replying to this email, we now have a Letter to Editors section where you can register your opinion publicly.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,900+ biopharma pros reading Endpoints daily — and it's free.